| The application of ferroptosis in diseases Y Qiu, Y Cao, W Cao, Y Jia, N Lu Pharmacological Research 159, 104919, 2020 | 332 | 2020 |
| Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer Y Yao, Q Guo, Y Cao, Y Qiu, R Tan, Z Yu, Y Zhou, N Lu Journal of Experimental & Clinical Cancer Research 37, 1-14, 2018 | 91 | 2018 |
| Oroxylin A suppresses ACTN1 expression to inactivate cancer-associated fibroblasts and restrain breast cancer metastasis Y Cao, W Cao, Y Qiu, Y Zhou, Q Guo, Y Gao, N Lu Pharmacological Research 159, 104981, 2020 | 35 | 2020 |
| Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity Y Qiao, Y Qiu, J Ding, N Luo, H Wang, X Ling, J Sun, Z Wu, Y Wang, Y Liu, ... Nature communications 12 (1), 6360, 2021 | 31 | 2021 |
| CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK B Lin, Y Li, T Wang, Y Qiu, Z Chen, K Zhao, N Lu Oncogene 39 (37), 6024-6040, 2020 | 19 | 2020 |
| Correction to: Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer Y Yao, Q Guo, Y Cao, Y Qiu, R Tan, Z Yu, Y Zhou, N Lu Journal of Experimental & Clinical Cancer Research: CR 38, 2019 | 1 | 2019 |
| Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-beta signaling in breast cancer (vol 37, 282, 2018) Y Yao, Q Guo, Y Cao, Y Qiu, R Tan, Z Yu, Y Zhou, N Lu JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 38 (1), 2019 | | 2019 |
